Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference
Radio-DARPin MP0712 against DLL3, in co-development with Orano Med, to enter first-in-human study in 2025 Mesothelin named as second target in Radio-DARPin pipeline, program to be co-developed with Orano Med